Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067169 | 0.97 | AR (0.44) | AR | |
| SCHEMBL21531757 | 0.92 | AR (0.44) | AR | |
| SCHEMBL21531823 | 0.90 | AR (0.46) | AR | |
| SCHEMBL14949999 | 0.87 | S1PR1 (0.42) | — | |
| SCHEMBL18804890 | 0.84 | AR (0.46) | AR | |
| SCHEMBL19807342 | 0.84 | RET (0.47) | AR | |
| SCHEMBL2950177 | 0.81 | PPARA (0.50) | AR | |
| SCHEMBL2950197 | 0.80 | RET (0.46) | AR | |
| SCHEMBL14953272 | 0.80 | SLC22A12 (0.53) | AR | |
| SCHEMBL2943421 | 0.80 | AR (0.43) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317074-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2021-10-14 | — | — | US | disclosed |
| US-11034647-B2 | Histone acetyltransferase activators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-15 | — | — | US | disclosed |
| US-10640457-B2 | Histone acetyltransferase activators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200115325-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-16 | — | — | US | disclosed |
| EP-2509590-B1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20130121919-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130121919-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011072243-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034647-B2 | Histone acetyltransferase activators and uses thereof | EP300, KAT2A, NAA40 | AR 1034/4885 |
| US-20200115325-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | AR 1034/4885 |
| US-10640457-B2 | Histone acetyltransferase activators and uses thereof | EP300, KAT2A, NAA40 | AR 1034/4885 |
| US-20210317074-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | AR 1034/4885 |
| US-20130121919-A1 | HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF | EP300, KAT2A, NAA40 | AR 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.